Medtronic PLC (NYSE:MDT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Medtronic PLC has received a consensus recommendation of "Moderate Buy" from 19 analysts, with an average twelve-month price target of $102.14.
• In recent insider trading, Director William R. Jellison purchased 2,500 shares of Medtronic at an average price of $92.37, increasing his ownership by 100% to a total of 5,000 shares.
• Medtronic recently reported $1.26 EPS for the quarter, exceeding analysts' expectations, with revenue of $8.58 billion, up 7.7% year-over-year.

Medtronic PLC (NYSE:MDT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nineteen analysts that are presently covering the company, MarketBeat reports. Eight analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $102.1429.

A number of research firms have weighed in on MDT. BTIG Research reiterated a "neutral" rating on shares of Medtronic in a research report on Friday, July 11th. UBS Group lifted their price target on shares of Medtronic from $94.00 to $95.00 and gave the company a "neutral" rating in a report on Wednesday, August 20th. William Blair raised shares of Medtronic to a "hold" rating in a report on Friday, July 11th. Leerink Partnrs raised Medtronic to a "strong-buy" rating in a report on Monday, June 16th. Finally, Wells Fargo & Company raised their price target on Medtronic from $98.00 to $100.00 and gave the company an "overweight" rating in a report on Wednesday, August 20th.

Medtronic Price Performance

Shares of MDT traded up $0.01 during mid-day trading on Friday, reaching $92.91. The stock had a trading volume of 4,922,548 shares, compared to its average volume of 7,609,480. The firm has a market cap of $119.17 billion, a price-to-earnings ratio of 25.59, a PEG ratio of 2.36 and a beta of 0.77. Medtronic has a 12 month low of $79.29 and a 12 month high of $96.25. The business has a fifty day moving average of $90.97 and a 200 day moving average of $88.14. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.03. The business had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The company's revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities analysts predict that Medtronic will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 17th. Shareholders of record on Friday, September 26th will be given a dividend of $0.71 per share. The ex-dividend date is Friday, September 26th. This represents a $2.84 annualized dividend and a yield of 3.1%. Medtronic's dividend payout ratio (DPR) is 78.24%.

Insider Buying and Selling at Medtronic

In other Medtronic news, Director William R. Jellison acquired 2,500 shares of the stock in a transaction on Monday, August 25th. The stock was acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the transaction, the director directly owned 5,000 shares of the company's stock, valued at $461,850. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares of the company's stock, valued at $3,261,621.70. This trade represents a 19.46% decrease in their position. The disclosure for this sale can be found here. 0.26% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medtronic

Institutional investors have recently made changes to their positions in the company. Commerce Bank lifted its holdings in shares of Medtronic by 1.7% in the 1st quarter. Commerce Bank now owns 145,984 shares of the medical technology company's stock worth $13,118,000 after acquiring an additional 2,429 shares during the last quarter. Brighton Jones LLC lifted its holdings in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company's stock worth $3,194,000 after acquiring an additional 37,265 shares during the last quarter. Insight Inv LLC lifted its holdings in shares of Medtronic by 84.2% in the 1st quarter. Insight Inv LLC now owns 27,456 shares of the medical technology company's stock worth $2,467,000 after acquiring an additional 12,550 shares during the last quarter. Korea Investment CORP lifted its holdings in shares of Medtronic by 24.1% in the 1st quarter. Korea Investment CORP now owns 1,141,565 shares of the medical technology company's stock worth $102,581,000 after acquiring an additional 221,568 shares during the last quarter. Finally, D Orazio & Associates Inc. bought a new stake in shares of Medtronic in the 1st quarter worth about $357,000. Institutional investors own 82.06% of the company's stock.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.